Close Menu

Two years ago, Pfizer announced it had partnered with biotech company Celldex to develop a brain cancer vaccine. At the time, many people thought the move heralded the beginning of pharmaceutical companies developing personalized treatments for patients, says Robert Langreth on Forbes' Treatments blog. But now Pfizer has dissolved the partnership, leaving Celldex to try and develop the drug on its own.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.

CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.

Researchers in France are developing a new, fast test for SARS-CoV-2 that initial testing indicates may be highly accurate, the Guardian says.

In Cell this week: analysis of fitness patterns among SARS-CoV-2 isolates, single-cell transcriptome analysis of immune features in COVID-19, and more.